- Home
- IMCR vs GRDN Comparison
IMCR vs GRDN Comparison
Compare IMCR & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- GRDN
- Stock Information
- Founded
- IMCR 2008
- GRDN 2004
- Country
- IMCR United Kingdom
- GRDN United States
- Employees
- IMCR N/A
- GRDN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- IMCR Health Care
- GRDN Consumer Staples
- Exchange
- IMCR Nasdaq
- GRDN Nasdaq
- Market Cap
- IMCR 1.7B
- GRDN 1.7B
- IPO Year
- IMCR 2021
- GRDN 2024
- Fundamental
- Price
- IMCR $33.50
- GRDN $29.04
- Analyst Decision
- IMCR Buy
- GRDN Strong Buy
- Analyst Count
- IMCR 9
- GRDN 3
- Target Price
- IMCR $62.38
- GRDN $27.00
- AVG Volume (30 Days)
- IMCR 350.0K
- GRDN 292.9K
- Earning Date
- IMCR 11-06-2025
- GRDN 11-10-2025
- Dividend Yield
- IMCR N/A
- GRDN N/A
- EPS Growth
- IMCR N/A
- GRDN N/A
- EPS
- IMCR N/A
- GRDN N/A
- Revenue
- IMCR $356,145,000.00
- GRDN $1,326,604,000.00
- Revenue This Year
- IMCR $29.99
- GRDN $16.33
- Revenue Next Year
- IMCR $8.85
- GRDN $2.10
- P/E Ratio
- IMCR N/A
- GRDN N/A
- Revenue Growth
- IMCR 26.78
- GRDN 18.53
- 52 Week Low
- IMCR $23.15
- GRDN $17.13
- 52 Week High
- IMCR $39.33
- GRDN $30.39
- Technical
- Relative Strength Index (RSI)
- IMCR 49.73
- GRDN 74.23
- Support Level
- IMCR $31.36
- GRDN $23.72
- Resistance Level
- IMCR $34.18
- GRDN $24.86
- Average True Range (ATR)
- IMCR 1.38
- GRDN 1.01
- MACD
- IMCR -0.00
- GRDN 0.52
- Stochastic Oscillator
- IMCR 60.51
- GRDN 97.91
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.